3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Rituximab
21
Cyclophosphamide
15
Etoposide
11
Vincristine
9
Prednisone
9
Doxorubicin
8
Cytarabine
8
Filgrastim
7
Radiotherapy
6
Peripheral Blood Stem Cell Transplantation
6
fludarabine phosphate
5
Melphalan
5
Dexamethasone
4
Carmustine
4
Bendamustine Hydrochloride
4
loncastuximab tesirine
3
ibrutinib
3
Tacrolimus
3
Stem Cell Transplantation
3
Mycophenolic Acid
3
Methotrexate
3
Gemcitabine
3
Calcium Dobesilate
3
CT-P10
3
Busulfan
3
venetoclax
2
sargramostim
2
polatuzumab vedotin
2
pembrolizumab
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma, Large B-Cell, Diffuse
×
navitoclax
×
Clear all
NCT01423539
2016-11-02
NAVIGATE
Genentech, Inc.
Phase 2
Withdrawn